Multi-Ethnic Study of Atherosclerosis

Tracy Murdoch O’Such returns to Diversified Search Group as Global Managing Partner

Retrieved on: 
Thursday, August 3, 2023
New media, Cablevision, Advertising, WISE, University, Digital, Culture, Communication, WICT, Chief digital officer, DSG, NAMIC, Multi-Ethnic Study of Atherosclerosis, Sport, Growth, National Association, Woman, Diversification, Global Media & Entertainment, Psychology

Philadelphia, PA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Diversified Search Group has announced that Tracy Murdoch O'Such is rejoining the firm and will serve as Global Managing Partner, leading both the firm's Media, Entertainment, and Sports practice , and expanding the firm's executive search capabilities in communications and marketing.

Key Points: 
  • Philadelphia, PA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Diversified Search Group has announced that Tracy Murdoch O'Such is rejoining the firm and will serve as Global Managing Partner, leading both the firm's Media, Entertainment, and Sports practice , and expanding the firm's executive search capabilities in communications and marketing.
  • O'Such returns to Diversified Search Group following a two-year hiatus working for a global boutique executive search firm.
  • "Tracy O'Such's return to Diversified Search Group at this transformational time, with our growing capabilities and expansion into key new markets, is a testament to our firm's unique position in the marketplace," says Aileen K. Alexander, CEO of Diversified Search Group.
  • "We’re thrilled that Tracy O’Such is rejoining us at DSG as an invaluable leader," says Judith M. von Seldeneck , Founder and Chair, Diversified Search Group.

UT Health Science Center San Antonio develops tool that counts brain lesions in seconds

Retrieved on: 
Friday, July 14, 2023
Taste, Jinn, Workforce, MESA, University, Vein, NeuroImage, University of Texas System, Workflow, Alzheimer's disease, University of Texas Health Science Center at San Antonio, Stroke, Deep learning, Cerebrovascular disease, NIA, UT Health San Antonio Cancer Center, Brain, Artery, Research, Cerebrospinal fluid, Radiology, Doctor of Philosophy, Movement, National Institute on Aging, Multi-Ethnic Study of Atherosclerosis, MRI, Dementia, Thalamus, Biggs, Alzheimer's Disease Neuroimaging Initiative, JAMA Network Open, Patient, Myenteric plexus, Map, SAN, School, Nursing, Artificial intelligence, Neurodegenerative disease, AI, System, Health, University of Texas Rio Grande Valley, Basal ganglia, Caregiver, Medical imaging, Medical device, Mobile phone, Atherosclerosis, Ageing

SAN ANTONIO, July 13, 2023 /PRNewswire-PRWeb/ -- An artificial intelligence (AI) tool developed at The University of Texas Health Science Center at San Antonio accurately counts brain lesions on MRI scans within seconds. Once it is adapted to the clinic, the AI tool should help neuroradiologists to evaluate patients' brain diseases at earlier stages.

Key Points: 
  • An innovative deep-learning tool developed by researchers at multiple institutions including The University of Texas Health Science Center at San Antonio promises to change this.
  • SAN ANTONIO, July 13, 2023 /PRNewswire-PRWeb/ -- An artificial intelligence (AI) tool developed at The University of Texas Health Science Center at San Antonio accurately counts brain lesions on MRI scans within seconds.
  • The AI tool leverages the power of UT Health Science Center San Antonio's Genie supercomputer, Habes said.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.

Stanton Chase Washington D.C. Announces Appointment of Iris Drayton-Spann to Managing Director

Retrieved on: 
Monday, July 10, 2023
Human resources, Bachelor, Society, WEL, Howard University, DC, Amanda, Mogul, Multimedia, Society for Human Resource Management, NAMIC, Non-governmental organization, Diversity, Multi-Ethnic Study of Atherosclerosis, WETA, DEI, National Association, Stanton Chase, George Washington University, Washington, D.C., Management, Iris

WASHINGTON, July 10, 2023 /PRNewswire/ -- The Washington D.C. Office of Stanton Chase, a top-10 retained executive search and consulting firm, announced Monday that Iris Drayton-Spann will be promoted from Director to Managing Director.

Key Points: 
  • WASHINGTON, July 10, 2023 /PRNewswire/ -- The Washington D.C. Office of Stanton Chase, a top-10 retained executive search and consulting firm, announced Monday that Iris Drayton-Spann will be promoted from Director to Managing Director.
  • As a part of Stanton Chase's Washington, DC team, Iris serves as an expert in non-profit, public media, human resources, and for-profit diversity executive placements and leadership consulting.
  • It is core to how I show up every day, with clients and candidates at Stanton Chase," she said.
  • Iris graduated from Howard University with a Bachelor's degree and George Washington University with a Master's.

Signifier Medical Technologies’ eXciteOSA®, the Only FDA-Authorized Daytime Therapy for Primary Snoring and Mild Obstructive Sleep Apnea, Demonstrates Real-World Adherence to Treatment of Over 80%

Retrieved on: 
Wednesday, September 21, 2022
FDA, Health Technology, Health, Medical Devices, Medical Affairs Bureau, Hypertension, Patient, Mask, Sleep, Research, Death, Placebo, Snoring, Company, Pittsburgh Sleep Quality Index, AHI, Obstructive sleep apnea, Continuous positive airway pressure, Health technology, Ageing, PAP, Risk, FDA, Sleep apnea, American Journal of Respiratory and Critical Care Medicine, Association, Population, Clinical trial, CPAP, Sama, Data, List of MDPI academic journals, Somnolence, Multi-Ethnic Study of Atherosclerosis, Marital status, Roy Taylor (scientist), American Journal, Epworth Sleepiness Scale, Stroke, NMES, Medicine, Mouth, Quality of life, Population health, Solution, Smoking, Multimedia, Education, Fasting, Pharmaceutical industry, Medical device, Signified and signifier, Atherosclerosis

The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.

Key Points: 
  • The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.
  • Sleep apnea is a serious condition, and adherence to treatment is both a challenge and a requirement.
  • We understand patients desire for effective treatments that fit their lifestyle, said Dr. Jessie Bakker, Executive Vice President of Medical Affairs at Signifier.
  • Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.

SomaLogic Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Company, Disease management, Forecasting, NGS, EBITDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Food, Nasdaq, Proteome, SomaLogic, Proteomics, Investment, Mission statement, Solution, Health, RUO, Science Translational Medicine, Investor, European Prospective Investigation into Cancer and Nutrition, Net, Partnership, EPIC, Forward-looking statement, Multi-Ethnic Study of Atherosclerosis, MESA, Technology, GAAP, Private Securities Litigation Reform Act, Twitter, Database, Growth, Security (finance), Annual report, GLOBE, Video game, Pharmaceutical industry, Bookkeeping, Risk management, Illumina, Atherosclerosis

BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March31, 2022.

Key Points: 
  • BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March31, 2022.
  • Gross margin for the three months ended March31, 2022, was 49.3% compared to 66.9% for the corresponding period of 2021.
  • ET on Thursday, May12, 2022, to discuss its first quarter 2022 financial results.
  • We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results used by management to evaluate and run the business, as well as, for financial planning purposes.

SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Tuesday, March 29, 2022
EBITDA, Private Securities Litigation Reform Act, Company, Mission statement, Lung, MESA, Investor, Investment, Forward-looking statement, Growth, GAAP, National Heart, Lung, and Blood Institute, Forecasting, Research, Strategic management, SomaLogic, Food, U.S. Securities and Exchange Commission, Senior, RUO, Net, Technology, Database, Twitter, National, Nasdaq, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Adjustment, Mergers and acquisitions, NHLBI, Development, Multi-Ethnic Study of Atherosclerosis, Annual report, Proteomics, Security (finance), Video game, Bank, Cryptocurrency, Bookkeeping, Risk management, Atherosclerosis

Gross margin for the three months ended December31, 2021 was 54.5% compared to 63.7% for the corresponding period of 2020.

Key Points: 
  • Gross margin for the three months ended December31, 2021 was 54.5% compared to 63.7% for the corresponding period of 2020.
  • The fourth quarter of 2020 benefited from higher revenue, primarily associated with the two large one-time sales described above.
  • Adjusted EBITDA was a loss of $27.7 million in the fourth quarter of 2021 compared with an adjusted EBITDA loss of $1.0 million in the corresponding period of 2020.
  • ET on Tuesday, March29, 2022 to discuss its fourth quarter 2021 financial results.

SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study

Retrieved on: 
Wednesday, February 2, 2022
University of Minnesota, SomaLogic, CAP, Food, NASDAQ, University, Wake Forest University, National, NASH, Columbia University, Twitter, MESA, Woman, Research, COVID-19, Population, Man, Clinical Laboratory, US Foods, Fatty liver disease, College, Risk, Proteome, Health, Cardiovascular disease, GLOBE, Knowledge, NHLBI, Johns Hopkins University, National Heart, Lung, and Blood Institute, UCLA, Multi-Ethnic Study of Atherosclerosis, Lung, Protein, CLIA, Nasdaq, Pharmaceutical industry, Northwestern University, Atherosclerosis

SomaLogic will use its industry-leading assay to analyze 105 million protein measurements from 15,000 samples spanning 15 years of clinical interactions.

Key Points: 
  • SomaLogic will use its industry-leading assay to analyze 105 million protein measurements from 15,000 samples spanning 15 years of clinical interactions.
  • The MESA study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
  • The MESA study is groundbreaking and we expect it to generate the largest proteomic dataset of an ethnically diverse population, said SomaLogic Chief Executive Officer Roy Smythe, M.D.
  • The MESA study is focused on subclinical cardiovascular disease and the risk factors that predict progression to clinical signs and symptoms.